Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05431010 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Efficacy on Walking Ability of Electroacupuncture Therapy in Elderly Patients With Sarcopenia

StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study Identification, Study Status, Oversightv8
  2. Primary completion date: Dec 31, 2024 to Dec 31, 2025
    • Study completion date: Dec 31, 2024 to Dec 31, 2026
    v7
  3. Re-verified, no change to tracked fieldsv6
  4. Primary completion date: Nov 9, 2024 to Dec 31, 2024v5
  5. Primary completion date: Nov 1, 2023 to Nov 9, 2024v4
Show 2 earlier versionsHide 2 earlier versions
  1. Primary completion date: Oct 1, 2023 to Nov 1, 2023v3
  2. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Jun 20, 2022 to Jul 2, 2022
    • Site details revised
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Introduction: The efficacy of existing therapies for the treatment of sarcopenia is still not satisfactory. Therefore, this randomized controlled, assessor-blinded study was designed to investigate the efficacy and safety of electroacupuncture(EA) therapy in elderly patients with sarcopenia. Methods and analysis: This randomized controlled trial will enroll 120 elderly patients with sarcopenia. Subjects will be randomly assigned in a 1:1 ratio to either EA combined with rehabilitation training group or rehabilitation training group through a central computerized randomization system. Primary outcome measure is lower limb mobility, including 6-minute walk test、timed get up and go test, and short physical performance battery. Secondary outcome measures include lower limb muscle mass and lower limb muscle strength. Outcome assessment will be conducted before the intervention, at 12 weeks after the intervention and at the end of the 12-week follow-up. Adverse reactions will be evaluated during the trial. Conclusion: This research will provide evidence to clarify whether EA is effective and safe in the treatment of sarcopenia.
Trial Details
NCT Number NCT05431010
Lead Sponsor The Third Affiliated hospital of Zhejiang Chinese Medical University
Conditions
(from sponsor)		 Sarcopenia
Related terms Sarcopenia
Enrollment 120 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov